Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

This trial tests a drug called zanzalintinib combined with paclitaxel (a standard chemotherapy) in women with high-grade uterine (womb) cancer that has come back after previous treatment. Zanzalintinib works by cutting off the blood supply that tumors need to grow. **You may be eligible if...** - You have been diagnosed with high-grade endometrial (uterine) cancer or uterine carcinosarcoma that has returned or spread - You have received 1 or 2 previous cancer treatment regimens, including at least one platinum-based chemotherapy - You have recovered from side effects of prior treatments - You are able to carry out daily activities without significant limitation **You may NOT be eligible if...** - You have received more than 2 prior lines of therapy - You have certain tumor types (like dMMR/MSI-H) and have not yet tried the required targeted drugs - You have uncontrolled medical conditions that could make treatment unsafe Talk to your doctor to see if this trial is right for you.